Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recent randomized controlled trials (RCTs) tested the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to specifically treat nonalcoholic fatty liver disease (NAFLD). We systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or head-to-head RCTs that used SGLT-2 inhibitors for treatment of NAFLD. No published RCTs with paired liver biopsy data were available for the meta-analysis. Primary outcome measures were changes in serum liver enzyme levels and liver fat content on imaging techniques. Overall, we included a total of twelve RCTs testing the efficacy of dapagliflozin (n = six RCTs), empagliflozin (n = three RCTs), ipragliflozin (n = two RCTs) or canagliflozin (n = one RCT) to specifically treat NAFLD for a median period of 24 weeks with aggregate data on 850 middle-aged overweight or obese individuals with NAFLD (90% with type 2 diabetes). Compared to placebo/reference therapy, treatment with SGLT-2 inhibitors significantly decreased serum alanine aminotransferase (weighted mean differences (WMD): −10.0 IU/L, 95%CI −12.2 to −7.79 IU/L; I2 = 10.5%) and gamma-glutamyltransferase levels (WMD: −14.49 IU/L, 95%CI −19.35 to −9.63 IU/L, I2 = 38.7%), as well as the absolute percentage of liver fat content on magnetic resonance-based techniques (WMD: −2.05%, 95%CI −2.61 to −1.48%; I2 = 0%). In conclusion, SGLT-2 inhibitors seem to be a promising treatment option for NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions in many parts of the world, and is estimated to affect up to ~70–80% of people with type 2 diabetes mellitus (T2DM) [1,2].”
BackgroundA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“histological resolution of NASH have recently been reported also in some phase-2 RCTs using glucagon-like peptide-1 receptor agonists, such as liraglutide and semaglutide [9,10].”
BackgroundTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 3×
“[19], the investigators reported only the placebo-corrected difference in mean percent MRI-PDFF with dapagliflozin.”
BackgroundMethodZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · cited 1×
“Among these individuals, 414 were randomly assigned to either placebo or reference therapy, whereas 436 were randomly assigned to active treatment with dapagliflozin (n = 6 RCTs [19,22,24,25,27,30]), empagliflozin (n = 3 RCTs [21,26,28]), ipragliflozin (n = 2 RCTs [20,29]) or canagliflozin (n = 1 RCT [23]) in order to…”
MethodMantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut · doi:10.1136/gutjnl-2020-322572 · Cited by 481
Self-citationNonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Self-citationEriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396 · cited 3×
“Therefore, a total of twelve RCTs (seven placebocontrolled studies [19,21,23–26,28] and five active-controlled studies [20,22,27,29,30]) were considered eligible for inclusion in the meta-analysis and were assessed for quality.”
BackgroundMethodKahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360 · cited 2×
“Among these individuals, 414 were randomly assigned to either placebo or reference therapy, whereas 436 were randomly assigned to active treatment with dapagliflozin (n = 6 RCTs [19,22,24,25,27,30]), empagliflozin (n = 3 RCTs [21,26,28]), ipragliflozin (n = 2 RCTs [20,29]) or canagliflozin (n = 1 RCT [23]) in order to…”
BackgroundMethodStine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.061 · Cited by 283 · cited 1×
“, NASH and fibrosis) is somewhat limited [39,40].”
BackgroundLatva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253 · cited 2×
“Among these individuals, 414 were randomly assigned to either placebo or reference therapy, whereas 436 were randomly assigned to active treatment with dapagliflozin (n = 6 RCTs [19,22,24,25,27,30]), empagliflozin (n = 3 RCTs [21,26,28]), ipragliflozin (n = 2 RCTs [20,29]) or canagliflozin (n = 1 RCT [23]) in order to…”
BackgroundMethodCusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204 · cited 2×
“Among these individuals, 414 were randomly assigned to either placebo or reference therapy, whereas 436 were randomly assigned to active treatment with dapagliflozin (n = 6 RCTs [19,22,24,25,27,30]), empagliflozin (n = 3 RCTs [21,26,28]), ipragliflozin (n = 2 RCTs [20,29]) or canagliflozin (n = 1 RCT [23]) in order to…”
BackgroundMethodLai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191
Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138 · cited 5×
“As SGLT-2 inhibitors improve not only glycemic control, but also body weight and blood pressure, a number of observational cohort studies and RCTs have recently examined the possible beneficial effects of this novel class of glucose-lowering medications in individuals with T2DM and NAFLD [7,17,18].”
BackgroundSelf-citationBril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.018 · Cited by 55 · cited 1×
“In addition, magnetic resonance-based techniques may not be as useful to assess treatment response in patients with NAFLD as previously believed, given that some evidence suggests that improvements in liver fat content measured by MRI do not necessarily translate in improvements in liver histology features (lobular in…”
BackgroundSGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48 · cited 4×
“Substantial evidence shows that the coexistence of T2DM and NAFLD synergistically increases the risk of developing not only the more severe histologic forms of NAFLD (nonalcoholic steatohepatitis [NASH], cirrhosis and hepatocellular carcinoma), but also the risk of developing cardiovascular disease and other chronic c…”
BackgroundInfluential
Research works printed but not linked: 29
- Non-alcoholic Fatty Liver Disease Study Group, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H., Grieco, A., and Machado, M.V. (2015). Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis., 47, 997–1006. · DOI · Paper page
- Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C.D., and Targher, G. (2020). Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. · DOI · Paper page
- Budd, 2020, Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease, Curr. Diab. Rep., 20, 59, 10.1007/s11892-020-01349-1 · DOI
- Cusi, 2020, A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions, Liver Int., 40, 82, 10.1111/liv.14350 · DOI · Paper page
- Scheen, 2020, Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus, Nat. Rev. Endocrinol., 16, 556, 10.1038/s41574-020-0392-2 · DOI · Paper page
- Schernthaner, 2016, EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus, Clin. Ther., 38, 1288, 10.1016/j.clinthera.2016.04.037 · DOI
- Zelniker, 2020, Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review, J. Am. Coll. Cardiol., 75, 435, 10.1016/j.jacc.2019.11.036 · DOI
- Wu, 2016, Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis, Lancet Diabetes Endocrinol., 4, 411, 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
- Zelniker, 2020, Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review, J. Am. Coll. Cardiol., 75, 422, 10.1016/j.jacc.2019.11.031 · DOI · Paper page
- Dougherty, 2021, A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease, Ann. Pharmacother., 55, 65, 10.1177/1060028020935105 · DOI · Paper page
- Ito, 2017, Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial, Diabetes Care, 40, 1364, 10.2337/dc17-0518 · DOI · Paper page
- Shimizu, 2019, Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease, Diabetes Obes. Metab., 21, 285, 10.1111/dom.13520 · DOI · Paper page
- Johansson, 2020, Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes, Diabetes Obes. Metab., 22, 1094, 10.1111/dom.14004 · DOI · Paper page
- Taheri, 2020, Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial, Adv. Ther., 37, 4697, 10.1007/s12325-020-01498-5 · DOI · Paper page
- Han, E., Lee, Y.H., Lee, B.W., Kang, E.S., and Cha, B.S. (2020). Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J. Clin. Med., 9. · DOI
- Kinoshita, 2020, Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study, J. Diabetes Investig., 11, 1612, 10.1111/jdi.13279 · DOI
- Gallo, 2020, Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials, Diabetes Ther., 11, 1849, 10.1007/s13300-020-00867-1 · DOI
- Li, 2018, Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials, J. Pharm. Pharm. Sci., 21, 222, 10.18433/jpps29831 · DOI · Paper page
- Raj, 2019, SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review, World J. Diabetes, 10, 114, 10.4239/wjd.v10.i2.114 · DOI · Paper page
- Scheen, 2019, Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications, Diabetes Metab., 45, 213, 10.1016/j.diabet.2019.01.008 · DOI · Paper page
- Ji, W., Zhao, M., Wang, M., Yan, W., Liu, Y., Ren, S., Lu, J., Wang, B., and Chen, L. (2017). Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE, 12. · DOI
- Swe, 2019, Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats, Clin. Sci., 133, 2415, 10.1042/CS20190863 · DOI
- Caussy, 2018, Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials, Hepatology, 68, 763, 10.1002/hep.29797 · DOI · Paper page
- Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, J. Hepatol., 65, 589, 10.1016/j.jhep.2016.05.013 · DOI · Paper page
- Mantovani, 2018, Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis, Metabolism, 79, 64, 10.1016/j.metabol.2017.11.003 · DOI · Paper page
- Lonardo, 2019, Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps, Hepatology, 70, 1457, 10.1002/hep.30626 · DOI · Paper page
- Markham, 2014, Luseogliflozin: First global approval, Drugs, 74, 945, 10.1007/s40265-014-0230-8 · DOI
- Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
- Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 · DOI · Paper page
Cited by
Metabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Self-citationMantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Self-citationThe current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
Liu, W., You, D., Lin, J., Zou, H., Zhang, L., Luo, S., Yuan, Y., Wang, Z., Qi, J., Wang, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.005 · Cited by 61
Metadata
- Authors
- Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2020-12-30
- Volume
- 11
- Issue
- 1
- Pages
- 22
- ISSN
- 2218-1989 (ISSN-L)
- OpenAlex
- W3115762316
- Cited by
- 134
- References
- 21
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.